LP
BEAM icon

LMR Partners’s Beam Therapeutics BEAM Stock Holding History

LMR Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,400
Closed -$674K – 1113
2024
Q1 		$674K Buy
+20,400
New +$636K 0.01% 728

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

LMR Partners's BEAM Position: Q4 2022 in Review

LMR Partners sold out of Beam Therapeutics (BEAM) in Q4 2022, closing a stake of 18,275 shares — an estimated $871K sold.

LMR Partners first reported a position in BEAM in Q2 2022 and held it in 2 quarters. The position peaked at $871K in Q3 2022. 209 funds tracked by Wall St. Rank hold BEAM as of Q4 2022.

  • LMR Partners reported no remaining Beam Therapeutics position as of Q4 2022 after selling out during the quarter.
  • LMR Partners sold 18,275 Beam Therapeutics shares in Q4 2022, an estimated $871K.
  • LMR Partners first reported a position in Beam Therapeutics in Q2 2022 and held it in 2 quarters.
  • LMR Partners's Beam Therapeutics position peaked at $871K in Q3 2022.
  • 209 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.